Snapshot from Jul 19, 2026 at 14:14 UTC. For live data and tracking: View Live
Events / Business / MindMaze Therapeutics European...
Business clinical study

MindMaze Therapeutics European Reimbursement Studies

Analysis based on 6 articles · First reported Jul 01, 2026 · Last updated Jul 01, 2026

Sentiment
60
Attention
4
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The enrollment of patients in these clinical studies by Coeptis Therapeutics Holdings is a positive development for the company, potentially leading to expanded market access and revenue in Europe. Successful reimbursement for at-home neurorehabilitation could significantly increase the addressable market for Coeptis Therapeutics Holdings's products, positively impacting its stock price. The studies also highlight the growing trend of technology integration in healthcare, which could benefit other companies in the medical technology and biotechnology sectors.

Biotechnology Healthcare
Event Summary

Coeptis Therapeutics Holdings has announced the enrollment of the first patients in two significant neurorehabilitation studies in Europe: the SwissNeuroRehab-HDHI study in Switzerland and the REACT-AVC study in France. These studies are pivotal to Coeptis Therapeutics Holdings's strategy to secure reimbursement for its at-home neurorehabilitation solutions in key European markets, mirroring its successful model in the United States. The SwissNeuroRehab study, backed by Switzerland — Innosuisse with CHF 11.2 million, is a national consortium evaluating high-dose, high-intensity neurorehabilitation across various care phases. The REACT-AVC study, conducted at Hospices Civils de Lyon, focuses on early outpatient and home-based stroke rehabilitation to generate evidence for the French healthcare system. These initiatives are part of a broader European ambition, with Coeptis Therapeutics Holdings also being a core partner in the pan-European Neurorehab4EU consortium.

Key Actions
90 Coeptis Therapeutics Holdings enrolled first patients SwissNeuroRehab
70 Switzerland — Innosuisse funded consortium SwissNeuroRehab
Entities Involved
stock
Coeptis Therapeutics Holdings
Coeptis Therapeutics Holdings is advancing its strategy to secure reimbursement for at-home neurorehabilitation solutions in Europe by enrolling patients in the SwissNeuroRehab and REACT-AVC studies. This move is expected to expand its market reach and revenue streams.
Importance 100.0 Sentiment 70.0
oth
SwissNeuroRehab
SwissNeuroRehab is a consortium that has enrolled the first patients in a High-Dose, High-Intensity (HDHI) neurorehabilitation study, which is powered by Coeptis Therapeutics Holdings's platform. This study is crucial for validating technology-supported neurorehabilitation pathways and securing reimbursement in Switzerland.
Importance 80.0 Sentiment 60.0
govactor
Switzerland — Innosuisse
Switzerland — Innosuisse is funding the SwissNeuroRehab consortium with CHF 11.2 million, supporting the development and validation of technology-supported neurorehabilitation pathways in Switzerland.
Importance 40.0 Sentiment 50.0
cnt
Switzerland
Switzerland is a key European market where Coeptis Therapeutics Holdings is focusing its efforts to obtain reimbursement for at-home neurorehabilitation through the SwissNeuroRehab study. The country's healthcare system is a target for market expansion.
Importance 40.0 Sentiment 20.0
cnt
France
France is another key European market where Coeptis Therapeutics Holdings is advancing its reimbursement strategy through the REACT-AVC study at Hospices Civils de Lyon. The French healthcare system is a target for market expansion.
Importance 40.0 Sentiment 20.0
oth
Neurorehab4EU
Neurorehab4EU is a pan-European consortium, of which Coeptis Therapeutics Holdings is a core partner, designed to scale software-enabled neurorehabilitation across European healthcare systems, including Switzerland, France, and Italy.
Importance 30.0 Sentiment 50.0
per
Andrea Serino
Professor Andrea Serino is the Coordinator of SwissNeuroRehab and Director of the Neurorehab Research Center at Lausanne University Hospital (CHUV). He emphasizes the importance of the study for payers and policymakers.
Importance 20.0 Sentiment 40.0
per
Olivier Bill
Dr. Olivier Bill is a Principal Investigator at Lausanne University Hospital (CHUV) for the SwissNeuroRehab study. He highlights the potential of technology to reshape post-stroke recovery and enable sustainable reimbursement.
Importance 20.0 Sentiment 40.0
per
Rose Henderson
Rose Henderson, CEO of Coeptis Therapeutics Holdings, stated the company's commitment to extending its neurotherapeutic platform's accessibility in Europe, building on its US success.
Importance 20.0 Sentiment 50.0
cnt
United States
The United States serves as a model for Coeptis Therapeutics Holdings's EU reimbursement strategy, as the company has already established CPT reimbursement codes for at-home utilization and generated real-world evidence there.
Importance 20.0 Sentiment 10.0
Relationships
Switzerland related ↔ France
Switzerland related ↔ United States
France strained allies ↔ United States France remains a core NATO ally of the United States but actively opposes Washington's unilateral military actions, part
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.